Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy
Fifteen patients with severe active Crohn's disease, refractory to conventional therapy, were given a 16 week course of cyclosporine ar an initial oral daily dose of 10 mg/kg, adjusted to maintain cyclosporine scrum trough levels between 100 and 200 ng/ml. Five patients withdrew early because o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1988-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1988/970381 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561697658765312 |
|---|---|
| author | Kevork M. Peltekian C. Noel Williams Allan S. MacDonald Peter D. Roy Elizabeth Czolpinska |
| author_facet | Kevork M. Peltekian C. Noel Williams Allan S. MacDonald Peter D. Roy Elizabeth Czolpinska |
| author_sort | Kevork M. Peltekian |
| collection | DOAJ |
| description | Fifteen patients with severe active Crohn's disease, refractory to conventional
therapy, were given a 16 week course of cyclosporine ar an initial oral daily
dose of 10 mg/kg, adjusted to maintain cyclosporine scrum trough levels between 100
and 200 ng/ml. Five patients withdrew early because of side effects, poor absorption or
noncompliance. T he remaining 10 patients all improved within four weeks as
measured by three different clinical indices: Crohn's Disease Activity Index, Simple
Index of Crohn's Disease Activity and Mean Score of Therapeutic Goals (MSTG).
Seven patients maintained this initial improvement and prednisone was either
reduced or discontinued. Four of these seven patients relapsed with in four weeks of
stopping cyclosporine, and three remain in remission after 75 ± 2 weeks. Side effects
were minor and easily reversible. When the various clinical and laboratory indices
were compared, MSTG was found to be the most useful index for the assessment of
therapy. Cyclosporine appears to be a safe and effective therapy in patients with severe
active Crohn's disease refractory to conventional therapy. |
| format | Article |
| id | doaj-art-3dd173310dec453da85aa1e03a51a1bd |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1988-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-3dd173310dec453da85aa1e03a51a1bd2025-02-03T01:24:29ZengWileyCanadian Journal of Gastroenterology0835-79001988-01-012151110.1155/1988/970381Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional TherapyKevork M. Peltekian0C. Noel Williams1Allan S. MacDonald2Peter D. Roy3Elizabeth Czolpinska4Departments of Medicine and Surgery, Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, CanadaDepartments of Medicine and Surgery, Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, CanadaDepartments of Medicine and Surgery, Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, CanadaDepartments of Medicine and Surgery, Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, CanadaDepartments of Medicine and Surgery, Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, CanadaFifteen patients with severe active Crohn's disease, refractory to conventional therapy, were given a 16 week course of cyclosporine ar an initial oral daily dose of 10 mg/kg, adjusted to maintain cyclosporine scrum trough levels between 100 and 200 ng/ml. Five patients withdrew early because of side effects, poor absorption or noncompliance. T he remaining 10 patients all improved within four weeks as measured by three different clinical indices: Crohn's Disease Activity Index, Simple Index of Crohn's Disease Activity and Mean Score of Therapeutic Goals (MSTG). Seven patients maintained this initial improvement and prednisone was either reduced or discontinued. Four of these seven patients relapsed with in four weeks of stopping cyclosporine, and three remain in remission after 75 ± 2 weeks. Side effects were minor and easily reversible. When the various clinical and laboratory indices were compared, MSTG was found to be the most useful index for the assessment of therapy. Cyclosporine appears to be a safe and effective therapy in patients with severe active Crohn's disease refractory to conventional therapy.http://dx.doi.org/10.1155/1988/970381 |
| spellingShingle | Kevork M. Peltekian C. Noel Williams Allan S. MacDonald Peter D. Roy Elizabeth Czolpinska Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy Canadian Journal of Gastroenterology |
| title | Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy |
| title_full | Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy |
| title_fullStr | Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy |
| title_full_unstemmed | Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy |
| title_short | Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy |
| title_sort | open trial of cyclosporine in patients with severe active crohn s disease refractory to conventional therapy |
| url | http://dx.doi.org/10.1155/1988/970381 |
| work_keys_str_mv | AT kevorkmpeltekian opentrialofcyclosporineinpatientswithsevereactivecrohnsdiseaserefractorytoconventionaltherapy AT cnoelwilliams opentrialofcyclosporineinpatientswithsevereactivecrohnsdiseaserefractorytoconventionaltherapy AT allansmacdonald opentrialofcyclosporineinpatientswithsevereactivecrohnsdiseaserefractorytoconventionaltherapy AT peterdroy opentrialofcyclosporineinpatientswithsevereactivecrohnsdiseaserefractorytoconventionaltherapy AT elizabethczolpinska opentrialofcyclosporineinpatientswithsevereactivecrohnsdiseaserefractorytoconventionaltherapy |